Stock

Eli Lilly gets nod to launch weight-loss drug in Hong Kong – Bloomberg News

Published

(Reuters) – Eli Lilly (NYSE:LLY) expects to start selling its weight-loss drug in Hong Kong as early as the end of this year, Bloomberg News reported on Sunday.

The company has received the Hong Kong government approval to sell its tirzepatide injections — branded as Mounjaro — in a device called Kwikpen for both long-term weight management and type 2 diabetes, Eli Lilly told Bloomberg in a statement.

This post appeared first on investing.com

In this article:

You May Also Like

Editor's Pick

Could Trump undermine the vote again? Harris’s legal team says it’s not worried.

Former president Donald Trump and his allies have filed hundreds of lawsuits, with more to come, seeking to tighten voting rules or disqualify voters....

October 21, 2024

Economy

BoE’s Greene sticks to view that rate cuts should be gradual

LONDON (Reuters) – Bank of England interest rate-setter Megan Greene said she still believed the central bank should take a cautious approach to cutting...

October 21, 2024

Economy

Dockworkers on East and Gulf Coast to return to work after reaching agreement on wages

Thousands of dockworkers on the East Coast and Gulf Coast will return to work after reaching a tentative agreement on wages, ending one of...

October 4, 2024

Editor's Pick

Trump falsely calls Harris ‘mentally impaired,’ prompting criticism

Republican presidential nominee Donald Trump criticized Vice President Kamala Harris’s mental capacity Saturday, falsely claiming she was born “mentally impaired” and comparing her actions...

September 29, 2024

Disclaimer: beneficialinvestmentnow.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2024 beneficialinvestmentnow.com

Exit mobile version